Clinical Trials · NCT07096063
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 887,132
- Start date
- Oct 2024
- Locations
- 1 site, United States
- Primary endpoint
- Composite of all-cause mortality, myocardial infarction or stroke (Tirzepatide vs. dulaglutide)